Delving into the Latest Updates on Aviscumine with Synapse

Overview

Basic Info

Drug Type

Recombinant protein

Synonyms

Mistletoe lectin recombinant, Recombinant mistletoe lectin, Recombinant viscumin

+ [7]

Target-

Action

inhibitors

Mechanism

28S rRNA inhibitors(28S rRNA inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersSkin and Musculoskeletal Diseases

Active Indication-

Inactive Indication

Malignant melanoma stage IVMetastatic colon cancerMetastatic Colorectal Carcinoma+ [1]

Originator Organization

Cytavis Biopharma GmbH

Active Organization-

Inactive Organization

Cytavis Biopharma GmbH

License Organization-

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 15587880

Source: *****

Sequence Code 14084475

Source: *****

This trial is designed as a phase II evaluation of the effect of CY-503 or placebo on progression free survival (PFS) defined as the time from start of treatment until the objective observation of progressive disease (PD) or death from any course in patients with chemotherapy-refractory metastatic colorectal cancer.

Start Date01 Jul 2009

Sponsor / Collaborator

Cytavis Biopharma GmbH

[+3]

NCT00658437

/ CompletedPhase 2

A Phase II Multicenter Study to Test Progression-free and Overall Survival of CY-503 in the Treatment of Patients With Unresectable Stage IV Metastatic Melanoma After Antineoplastic Treatment Failure

The trial is designed as a phase II evaluation of the effect of CY-503 on progression free survival (PFS) in patients with stage IV malignant melanoma after failure of prior therapy. The aim of the study is at least a rate of 25% (PFS >/= 3 months).

Start Date01 Apr 2008

Sponsor / Collaborator

Cytavis Biopharma GmbH

100 Clinical Results associated with Aviscumine

Login to view more data

100 Translational Medicine associated with Aviscumine

Login to view more data

100 Patents (Medical) associated with Aviscumine

Login to view more data

34

Literatures (Medical) associated with Aviscumine

03 Jul 2019·Evidence-Based Complementary and Alternative MedicineQ4 · MEDICINE

Mistletoe-Based Drugs Work in Synergy with Radio-Chemotherapy in the Treatment of GliomaIn VitroandIn Vivoin Glioblastoma Bearing Mice

Q4 · MEDICINE

ArticleOA

Author: Miemietz, Jennifer T. ; Schötterl, Sonja ; Huber, Stephan M. ; Mittelbronn, Michel ; Gall, Andrea ; Lentzen, Hans ; Ehrlich, Ingrid ; Naumann, Ulrike ; Wirsik, Naita M. ; Ilina, Elena I.

Background. Extracts fromViscum album L.(VE) are used in the complementary cancer therapy in Europe for decades. VE contain several compounds like the mistletoe lectins (MLs) 1-3 and viscotoxins and also several minor ingredients. Since mistletoe lectin 1 (ML-1) has been described as the main component of VE harboring antitumor activity, purified native or recombinant ML-1 has been recently used in clinical trials. MLs stimulate the immune system, induce cytotoxicity, are able to modify the expression of cancer-associated genes, and influence the proliferation and motility of tumor cells.Objective. In this study our goal was to determine anticancer effects of the VE ISCADOR Qu, of recombinant ML-1 (Aviscumine), and of native ML-1 in the treatment of glioblastoma (GBM), the most common and highly malignant brain tumor in adults. Additionally we were interested whether these drugs, used in combination with a temozolomide-(TMZ)-based radio-chemotherapy, provide synergistic effects.Methods. Cell culture assays,ex vivomurine hippocampal brain slice cultures, human GBM cryosections, and a xenograft orthotopic glioblastoma mouse model were used.Results. In cells, the expression of the ML receptor CD75s, which is also expressed in GBM specimen, but not in normal brain, correlates with the drug-induced cytotoxicity. In GBM cells, the drugs induce cell death in a concentration-dependent manner and reduce cell growth by inducing cell cycle arrest in the G2/M phase. The cell cycle arrest was paralleled by modifications in the expression of cell cycle regulating genes. ML containing drugs, if combined with glioma standard therapy, provide synergistic and additive anticancer effects. Despite not reaching statistical significance, a single intratumoral application of Aviscumine prolonged the median survival of GBM mice longer than tumor irradiation. Moreover, intratumorally applied Aviscumine prolonged the survival of GBM-bearing mice if used in combination with irradiation and TMZ for further 6.5 days compared to the radio-chemotherapy.Conclusion. Our results suggest that an adjuvant treatment of glioma patients with ML-containing drugs might be beneficial.

01 Jan 2018·Evidence-Based Complementary and Alternative MedicineQ4 · MEDICINE

Adjuvant Therapy Using Mistletoe Containing Drugs Boosts the T‐Cell‐Mediated Killing of Glioma Cells and Prolongs the Survival of Glioma Bearing Mice

Q4 · MEDICINE

ArticleOA

Author: Schötterl, Sonja ; Huber, Stephan M ; Lentzen, Hans ; Mittelbronn, Michel ; Naumann, Ulrike

Viscum album L. extracts (VE) are applied as complementary cancer therapeutics for more than one century. Extracts contain several compounds like mistletoe lectins (ML) 1‐3 and viscotoxins, but also several minor ingredients. Since ML‐1 has been described as one of the main active components harboring antitumor activity, purified native or recombinant ML‐1 has been also used in clinical trials in the last years. The present study examined and compared the immunoboosting effects of three ML‐1 containing drugs (the extract ISCADOR Qu, the recombinant ML‐1 Aviscumine, and purified native ML‐1) in the context of the T‐cell mediated killing of glioma cells. Additionally we examined the possible underlying T‐cell stimulating mechanisms. Using cocultures of immune and glioma cells, a PCR‐based microarray, quantitative RT‐PCR, and an antibody‐based array to measure cytokines in blood serum, immunosupporting effects were determined. A highly aggressive, orthotopic, immunocompetent syngeneic mouse glioma model was used to determine the survival of mice treated with ISCADOR Qu alone or in combination with tumor irradiation and temozolomide (TMZ). Treatment of glioblastoma (GBM) cells with ISCADOR Qu that contains a high ML concentration, but also viscotoxins and other compounds, as well as with Aviscumine or native ML‐1, enhanced the expansion of cancer cell‐specific T‐cells as well as T‐cell‐mediated tumor cell lysis, but to a different degree. In GBM cells all three ML‐1‐containing preparations modulated the expression of immune response associated genes. In vivo, subcutaneous ISCADOR Qu injections at increasing concentration induced cytokine release in immunocompetent VM/Dk‐mice. Finally, ISCADOR Qu, if applied in combination with tumor irradiation and TMZ, further prolonged the survival of glioma mice. Our findings indicate that ML‐1 containing drugs enhance anti‐GBM immune responses and work in synergy with radiochemotherapy. Therefore, adjuvant mistletoe therapy should be considered as an auspicious treatment option for glioma patients.

01 Feb 2017·International Journal of OncologyQ2 · MEDICINE

Viscumins functionally modulate cell motility-associated gene expression

Q2 · MEDICINE

Article

Author: Mittelbronn, Michel ; Schötterl, Sonja ; Naumann, Ulrike ; Veninga, Vivien ; Armento, Angela ; Hübner, Miriam ; Wirsik, Naita Maren ; Bernatz, Simon ; Lentzen, Hans

In Europe extracts from Viscum album L., the European white-berry mistletoe, are widely used as a complementary cancer therapy. Viscumins (mistletoe lectins, ML) have been scrutinized as important active components of mistletoe and exhibit a variety of anticancer effects such as stimulation of the immune system, induction of cytotoxicity, reduction of tumor cell motility as well as changes in the expression of genes associated with cancer development and progression. By microarray expression analysis, quantitative RT-PCR and RT-PCR based validation of microarray data we demonstrate for the Viscum album extract Iscador Qu and for the lectins Aviscumine and ML-1 that in glioma cells these drugs differentially modulate the expression of genes involved in the regulation of cell migration and invasion, including processes modulating cell architecture and cell adhesion. A variety of differentially expressed genes in ML treated cells are associated with the transforming growth factor (TGF)-β signaling pathway or are targets of TGF-β. ML treatment downregulated the expression of TGF-β itself, of the TGF-β receptor II (TGFBR2), of the TGF-β intracellular signal transducer protein SMAD2, and of matrix-metalloproteinases (MMP) MMP-2 and MMP-14. Even if the changes in gene expression differ between Aviscumine, Iscador Qu and ML-1, the overall regulation of motility associated gene expression by all drugs showed functional effects since tumor cell motility was reduced in a ML-dependent manner. Therefore, ML containing compounds might provide clinical benefit as adjuvant therapeutics in the treatment of patients with invasively growing tumors such as glioblastomas.

100 Deals associated with Aviscumine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB12684

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metastatic colon cancer	Phase 2	Austria	Cytavis Biopharma GmbH	01 Jul 2009
Metastatic colon cancer	Phase 2	Germany	Cytavis Biopharma GmbH	01 Jul 2009
Metastatic Colorectal Carcinoma	Phase 2	Austria	Cytavis Biopharma GmbH	01 Jul 2009
Metastatic Colorectal Carcinoma	Phase 2	Germany	Cytavis Biopharma GmbH	01 Jul 2009
Malignant melanoma stage IV	Phase 2	Germany	Cytavis Biopharma GmbH	01 Apr 2008
Metastatic melanoma	Phase 2	Germany	Cytavis Biopharma GmbH	01 Apr 2008

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AACR2023	Phase 1	Advanced cancer	-	Intravenous Mistletoe (Helixor M)	gbeuwnweie(mknzohaofc) = 9.5% lbwbthpylr (rmbvptukxi ) View more	-	04 Apr 2023
NCT00658437 (AACR2016)	Phase 2	Metastatic melanoma	32	Aviscumine	bdkbucnxtq(stsdcbmwji) = skin reactions were monitored as adverse events ajmnpjudgn (cuxagltcoc )	Positive	15 Jul 2016
NCT00658437 (Pubmed \| J Immunother Cancer)	Phase 2	Unresectable Melanoma	32	Aviscumine	(dmlxgjyeoe) = oerluafefw wnfbszwixy (qeazoemhrb, 210 - 604) View more	-	01 Jan 2014
ASCO2010	Phase 2	Metastatic melanoma	32	CY-503	(ljfypvxqtm) = wbjxsmugxs enutwajkvn (sgveoijtrm )	-	20 May 2010

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data